



**HAL**  
open science

## Public opinion on global rollout of COVID-19 vaccines

Philip Clarke, Laurence Roope, Peter Loewen, Jean-François Bonnefon, Alessia Melegaro, Jorge Friedman, Mara Violato, Adrian Barnett, Raymond Duch

► **To cite this version:**

Philip Clarke, Laurence Roope, Peter Loewen, Jean-François Bonnefon, Alessia Melegaro, et al.. Public opinion on global rollout of COVID-19 vaccines. *Nature Medicine*, 2021, 27, pp.933-938. 10.1038/s41591-021-01322-9 . hal-03261784

**HAL Id: hal-03261784**

**<https://hal.science/hal-03261784>**

Submitted on 16 Jun 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

May 2021

“Public opinion on global rollout of COVID-19 vaccines”

Philip M Clarke, Laurence SJ Roope, Peter Loewen, Jean-Francois  
Bonneton, Alessia Melegaro, Jorge Friedman, Mara Violato,  
Adrian Barnett and Raymond Duch

# Public opinion on global rollout of COVID-19 vaccines

Philip M Clarke PhD,<sup>1</sup> Laurence SJ Roope PhD<sup>1</sup>, Peter Loewen PhD<sup>2</sup>, Jean-Francois Bonnefon PhD<sup>3</sup>, Alessia Melegaro PhD<sup>4</sup>, Jorge Friedman PhD<sup>5</sup>, Mara Violato PhD<sup>1</sup>, Adrian Barnett PhD<sup>6</sup> and Raymond Duch PhD<sup>7</sup>

1. Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford.
2. Department of Political Science and the Munk School of Global Affairs & Public Policy, University of Toronto.
3. Toulouse School of Economics
4. Department of Social and Political Sciences, University of Bocconi.
5. Facultad de Administración y Economía, Universidad de Santiago de Chile.
6. Queensland University of Technology, Australia
7. Nuffield College, University of Oxford.

Email address of corresponding author: [philip.clarke@ndph.ox.ac.uk](mailto:philip.clarke@ndph.ox.ac.uk)

To the editor - High-income countries' (HIC) COVID-19 vaccination programs have benefited from their ability to secure contracts for preferential supply for several vaccines.<sup>1</sup> For the rest of the world, vaccine access is much less certain. While G20 leaders have pledged to ensure fair distribution of COVID-19 vaccines worldwide, substantial challenges remain. The COVAX Facility aims to ensure all countries will have equal access and competes with high-income countries to acquire doses, but some low-income countries (LIC) may need to wait until at least next year before even the most vulnerable 20% of their populations are vaccinated.<sup>2</sup>

There are increasing calls for HIC to donate a proportion of their vaccine doses. In the H1N1 pandemic there was a co-ordinated effort among HIC to make a vaccine to protect the world's poorest, including a pledge by President Obama to donate 10% of the United States' vaccine supply; this was supported by the general public.<sup>3</sup>

A key factor that could shape the willingness of governments to make COVID-19 vaccines available to LICs is their public's willingness to support donations. We provide evidence on this issue with an international internet-based survey<sup>4</sup> that was conducted between 24 Nov and 28 Dec 2020. The overall study involved 15,536 individuals from 13 countries who completed an anonymous survey using Qualtrics web-based software. Quota sampling (and in five countries additional weighting) was used to obtain a sample that reflected the distribution of age, education, gender and region in each country.

We obtained information from 8,209 adult individuals from a subset of seven high-income countries (Australia, Canada, France, Italy, Spain, UK, US). The survey used a Visual Analogue Scale to measure agreement (from 0: 'very much disagree' to 100: 'very much agree') with three prioritization principles for the global allocation of COVID-19 treatments and vaccines. We asked if these should be first provided for: (i) "those who need them most"; (ii) "those who cannot afford to buy them"; (iii) "those who live in the country in which they are first developed". Secondly, we adapted a question previously used in the context of H1N1<sup>3</sup> and asked whether respondents supported donating some COVID-19 vaccine doses for distribution to poor countries with insufficient resources to buy their own vaccines. Those willing to donate indicated whether they favoured an amount greater than, equal to, or less than 10% of their

country's doses. Proportions and means, including 95% CIs, are reported, and the data used to estimate these statistics are available from the authors upon request.

Regarding the global allocation criteria for vaccines, the highest average level of agreement is based on need (with average agreement ranging from 70 (95% CI 68-71) to 80 (95% CI 78-81); then affordability (62 (95% CI 60-64) to 70 (95% CI 68-71)); and finally whether the country developed the vaccine (28 (95% CI 26-29) to 58 (95% CI 56-60)). This ranking is consistent across all countries. Table 1 shows the opinions regarding donation of purchased vaccines. The proportions supporting donation were more than double the proportions who did not support donating.

While current supplies are limited, many HIC have pre-purchased supplies exceeding their population size. For example, the US has reserved more than 1.2 billion doses<sup>5</sup> and Canada has premarket commitments covering more than nine doses per person.<sup>1</sup> Redistributing some of these supplies would have global benefits. It would reduce the risk of the emergence and spread of new variants and, according to predictions, benefit the economy, both globally and in donor countries.<sup>6</sup> In contrast, the economic cost of vaccine nationalism (where a few countries push to gain preferential access) is potentially high, with a recent report suggesting it could cost up to \$1.2 trillion per year to the world's economy.<sup>7</sup>

While we did not investigate opinions regarding the timing of donations, national vaccination strategies should be taking into account these broader benefits. Notably, countries such as Norway<sup>8</sup> have already pledged to distribute vaccines at the same time as vaccinating their own populations. Such policies are likely to maximize global health benefits. A recent modelling study suggests that allocating doses internationally in proportion to countries' population sizes would be a close to optimal strategy in terms of averting deaths.<sup>9</sup>

Like prevalence studies, these opinions represent a single point in time but, importantly, our survey was conducted at a time when the distribution of COVID-19 vaccines was no longer a hypothetical question. More broadly, understanding and potentially influencing public opinion will be important components of any strategies to combat COVID-19 and prevent future pandemics.<sup>10</sup> This global problem requires global solutions and our survey indicates that redistribution of some pre-purchased vaccine to countries most in need has public support.

**Table 1 Preferences of public regarding donation of vaccines governments has purchased by country**

Country % (95 CI)	Willing to donate				Not willing to donate	Don't Know	Prefer not to say
	< 10%	10%	> 10%	Any level*			
Australia	10 (8 12)	21 (18 23)	20 (18 22)	51 (48 54)	20 (17 22)	27 (24 29)	3 (2 4)
Canada	15 (13 17)	26 (23 28)	15 (13 18)	56 (53 59)	20 (18 23)	22 (19 24)	2 (1 3)
France	11 (9 13)	16 (14 19)	21 (18 23)	48 (45 51)	20 (17 22)	28 (25 31)	4 (3 5)
Italy	13 (11 15)	19 (16 21)	22 (19 25)	54 (50 57)	15 (13 18)	28 (25 31)	3 (2 4)
Spain	11 (9 13)	25 (23 28)	18 (16 21)	55 (52 58)	15 (13 17)	23 (21 26)	7 (5 8)
United Kingdom	14 (12 16)	21 (19 24)	16 (13 18)	51 (48 54)	26 (23 29)	22 (19 24)	1 (1 2)
United States	10 (8 12)	19 (16 22)	22 (20 25)	52 (48 55)	17 (15 20)	25 (22 28)	6 (4 8)

Notes: \*Any level combines responses from <10%, 10% and >10% categories; Based on data from CANDOUR study, for details see <https://oxford-candour.com/>; Sample sizes: Australia (1364); Canada (1150); France (1145); Italy (1081); Spain (1153); UK (1165); US (1150).

## References

1. Mullard, A. *Nature* <https://www.nature.com/articles/d41586-020-03370-6> (30 Nov 2020).
2. *Nature* **589**, 170 (2021).
3. Kumar, S., Quinn, S.C., Kim, K.H. & Hilyard, K.M. *PLOS ONE* **7**, e33025 (2012).
4. Duch, R. et al. Who should be first in line for the COVID-19 vaccine? Surveys in 13 countries of the public's preferences for prioritisation. Preprint at <https://www.medrxiv.org/content/10.1101/2021.01.31.21250866v1> (2021).
5. Duke Global Health Innovation Center. Launch and Scale Speedometer. Duke University. <https://launchandscalefaster.org/COVID-19> [Accessed 9 March 2020].
6. Çakmaklı, C., Demiralp, S., Kalemli-Özcan, S., Yeşiltaş, S. & Yıldırım, M.A. The economic case for global vaccinations: An epidemiological model with international production networks. National Bureau of Economic Research Working Paper No. number 28395 doi: 10.3386/w28395 (2021).
7. Hafner, M., Yerushalmi, E., Fays, C., Dufresne, E., Van Stolk, C. COVID-19 and the cost of vaccine nationalism. Santa Monica, CA: RAND Corporation, 2020. Available at

[https://www.rand.org/pubs/research\\_reports/RRA769-1.html](https://www.rand.org/pubs/research_reports/RRA769-1.html) [Accessed 18th December 2020]

8. Rigby, J. & Newey, S. *The Telegraph* <https://www.telegraph.co.uk/global-health/science-and-disease/norway-share-covid-19-vaccine-poorer-countries-time-protecting/> (20 January 2021).

9. Hogan, A.B. et al. Modelling the allocation and impact of a COVID-19 vaccine. Imperial College London <https://doi.org/10.25561/82822> (25 September 2020).

10. Bonell, C. et al. *J Epidemiol Community Health* **74**, 617-619 (2020).

### **Acknowledgements:**

The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and the COVID-19 Oxford Vaccine Trial. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. We acknowledge the support of the Office of the Dean of the Faculty of Arts & Science at the University of Toronto. J.-F.B. acknowledges support from the grant ANR-17-EURE-0010 Investissements d’Avenir. Jorge Friedman received funding from the University of Santiago project Dicyt USA1899. Alessia Melegaro acknowledges support from the Italian Ministry of Education Progetti di Rilevante Interesse Nazionale (PRIN), grant number 20177BRJXS. Mara Violato receives funding from the National Institute for Health Research (NIHR) Applied Research Collaboration Oxford and Thames Valley at Oxford Health NHS Foundation Trust. The survey study was approved by the University of Oxford Medical Sciences Interdivisional Research Ethics Committee (Approval ID: R72328/RE001).

**Editorial note:** this correspondence was peer reviewed.